Certara(US:CERT) Globenewswireยท2025-08-06 20:15Core Insights - Certara, Inc. reported strong financial results for Q2 2025, with total revenue of $104.6 million, reflecting a year-over-year growth of 12% on a reported basis and 10% on a constant currency basis [4][8] - The company continues to see significant interest in model-informed drug development, with expectations for sustainable long-term growth driven by software enhancements and new product introductions [3][4] - Certara's adjusted EBITDA for Q2 2025 was $31.9 million, an increase of 21% compared to the same period in 2024, indicating improved operational efficiency [9][11] Financial Performance - Total revenue for Q2 2025 was $104.6 million, up from $93.3 million in Q2 2024, marking a 12% increase [4][8] - Software revenue reached $46.7 million, a 22% increase year-over-year, while services revenue was $57.9 million, growing by 5% [5][8] - Total bookings for Q2 2025 were $112.0 million, representing a 13% increase from the previous year, with software bookings at $46.6 million (11% growth) and services bookings at $65.4 million (15% growth) [6][7] Cost and Expenses - Total cost of revenues for Q2 2025 was $40.7 million, slightly up from $39.8 million in Q2 2024 [7][8] - Total operating expenses decreased to $54.3 million from $62.5 million in the same quarter last year, primarily due to a reduction in contingent consideration and transaction costs [8][10] - The net loss for Q2 2025 was $2.0 million, significantly improved from a net loss of $12.6 million in Q2 2024 [10][11] Outlook - Certara expects full-year 2025 revenue to be in the range of $415 million to $425 million, with an adjusted EBITDA margin of 30-32% and adjusted diluted earnings per share projected between $0.42 and $0.46 [15][13] - The company is confident in its full-year plan, supported by growing commercial momentum and sustained demand for its solutions [3][4]